OriCell Therapeutics develops CAR-T cell therapies targeting GPRC5D and GPC3 to treat relapsed or refractory multiple myeloma and advanced liver cancer, addressing the unmet clinical needs in these patient populations. Their proprietary technology platform enhances T cell efficacy and persistence, aiming to provide effective and affordable treatment options for tumor immunotherapy.
Funding
$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Relapsed or refractory multiple myeloma and advanced liver cancer have limited effective treatment options, leading to unmet clinical needs for patients. Current tumor immunotherapy approaches may lack sufficient efficacy and persistence to provide long-term benefits.
Solution
OriCell Therapeutics develops innovative CAR-T cell therapies designed to target GPRC5D and GPC3, addressing the unmet needs in relapsed or refractory multiple myeloma and advanced liver cancer. The company's proprietary technology platform is engineered to enhance T cell efficacy, improve persistence, and provide more effective and affordable treatment options for patients. OriCAR-017, a GPRC5D-targeted CAR-T therapy, has received both FDA Fast Track and Orphan Drug designations, as well as NMPA IND approval for clinical trials. Ori-C101, a GPC3-targeted CAR-T therapy, is in clinical development for advanced liver cancer.
Target Audience
The primary target audience includes patients with relapsed or refractory multiple myeloma and advanced liver cancer, as well as the physicians and healthcare providers who treat them.
Features
- OriCAR-017: GPRC5D-targeted CAR-T therapy for relapsed or refractory multiple myeloma
- Ori-C101: GPC3-targeted CAR-T therapy for advanced liver cancer
- Proprietary OriAb and OriCAR technology platforms for antibody screening, optimization, and enhanced T cell function
- Designed to improve T cell infiltration, persistence, and tumor-killing capabilities
- CMC capabilities for scalable CAR-T cell manufacturing to meet clinical demands